AbCellera Biologics Inc. (ABCL) SEC Filings

AbCellera Biologics Inc. (ABCL) director John S. Montalbano reported purchasing 10,000 Common Shares on 2026-08-18 at $11.03 per share in an open-market or private transaction. After this purchase, he directly holds 251,000 Common Shares, and there is an additional 5,000 Common Shares reported as indirectly owned by his spouse. The filing indicates these transactions were not reported under a Rule 10b5-1 trading plan.

AbCellera Biologics Inc. Chief Financial Officer Andrew Booth purchased 37,200 Common Shares on August 14, 2026 at $10.32 per share in an open market or private transaction. Following this trade, he holds 482,800 Common Shares directly and 130,959 Common Shares indirectly, held by his spouse.

AbCellera Biologics Inc. director Michael R. Hayden reported an indirect open-market purchase of 46,387 Common Shares of AbCellera on August 12, 2026 at a weighted-average price of $10.37 per share, with individual trade prices ranging from $10.25 to $10.45.

The acquired shares are held by Genworks 2 Consulting, Inc., over which Hayden’s spouse has sole voting and investment power. Hayden reports 1,319,784 Common Shares held indirectly through Genworks 2 following the transaction and separately 118,245 Common Shares held indirectly by his spouse, and disclaims beneficial ownership of these securities except for any indirect pecuniary interest.

AbCellera Biologics Inc. entered into an underwriting agreement for an underwritten public offering of 17,435,897 common shares at $9.75 per share and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,076,926 common shares at $9.74999 per warrant.

All securities are being sold by AbCellera, with expected gross proceeds of $200.0 million and estimated net proceeds of approximately $187.0 million. Each pre-funded warrant is immediately exercisable for one common share at an exercise price of $0.00001 per share and is subject to a 4.99% beneficial ownership cap, adjustable up to 19.99% with 61 days’ notice. The offering, made under a shelf registration statement on Form S-3ASR, is expected to close on or about August 14, 2026, and AbCellera has agreed to a 60-day lock-up on additional share sales, subject to exceptions.

AbCellera Biologics Inc. is conducting a primary offering of 17,435,897 common shares and pre-funded warrants to purchase up to 3,076,926 common shares under its automatic shelf registration. Securities are priced at $9.75 per share and $9.74999 per pre-funded warrant, for aggregate gross proceeds of $199,999,993.48. After underwriting discounts and estimated expenses, AbCellera expects net proceeds of approximately $187.0 million, which it intends to use, together with existing cash, to fund research, development and clinical advancement of its internal pipeline, including lead program ABCL635, and for working capital and general corporate purposes.

The pre-funded warrants are immediately exercisable at $0.00001 per share, subject to a 4.99%–19.99% beneficial ownership cap, and will not be listed for trading. As of June 30 2026, AbCellera had 306,469,632 common shares outstanding and net tangible book value of $811.7 million, or $2.65 per share. Giving effect to this offering (excluding warrant exercises), as-adjusted net tangible book value would be $998.7 million, or $3.08 per share, implying immediate dilution of $6.67 per share to new investors. The company highlights recently announced positive Phase 2 topline results for ABCL635 in menopausal vasomotor symptoms, where a single 600 mg dose produced statistically significant improvements in hot-flash frequency, severity, sleep and patient-reported outcomes with a favorable safety profile.

AbCellera Biologics Inc. director Michael R. Hayden reported a bona fide charitable gift of 50,000 Common Shares on August 11, 2026. The donation was made by Genworks 2 Consulting, Inc., which now holds 1,273,397 Common Shares. These shares are held with sole voting and investment power by the reporting person’s spouse, and the reporting person disclaims beneficial ownership except for any indirect pecuniary interest. A separate indirect holding of 118,245 Common Shares is reported as held by the spouse.

AbCellera Biologics Inc. is conducting a primary offering of $200,000,000 of common shares and, for certain investors, pre-funded warrants to purchase common shares under its automatic shelf registration. Each pre-funded warrant is exercisable immediately for one common share at an exercise price of $0.00001 per share and is priced at the common share offering price minus $0.00001. The warrants will not be listed and are subject to ownership caps of 4.99% or 9.99%, increaseable up to 19.99% with notice.

AbCellera is a clinical-stage biotechnology company focused on antibody-based medicines. As of June 30, 2026, it had 306,469,632 common shares outstanding and net tangible book value of $811.7 million, or $2.65 per share. Recent top-line Phase 2 data for lead program ABCL635 in menopausal vasomotor symptoms showed an 8.8 mean daily reduction in moderate/severe hot flashes at week 4 versus 3.5 on placebo, with an 83% versus 33% mean percent reduction in frequency and favorable safety.

Net proceeds, excluding any nominal warrant exercise proceeds, are expected to be used with existing cash to fund internal pipeline R&D and clinical advancement, particularly ABCL635, and for working capital and general corporate purposes. The company highlights dilution risk from this and future equity offerings and reiterates that it does not expect to pay dividends in the foreseeable future.

AbCellera Biologics Inc. reported positive Phase 2 results for ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody being developed as a non-hormonal, long-acting subcutaneous treatment for moderate-to-severe vasomotor symptoms (VMS) due to menopause. In a randomized, double-blind, placebo-controlled trial of 92 postmenopausal women (46 ABCL635, 46 placebo), a single 600 mg dose met the primary efficacy endpoints at week 4.

ABCL635 reduced VMS frequency by a mean of 8.8 moderate/severe hot flashes per day from baseline versus 3.5 for placebo, a placebo-adjusted difference of 5.3 and an 83% vs 33% mean percent reduction. Severity improved with a mean reduction of 1.4 points vs 0.3 for placebo, and mean percent reduction of 58% vs 12%. At week 4, 84% of ABCL635 patients rated symptoms as “Much Better” or “Moderately Better” versus 27% on placebo, and sleep disturbance scores improved with a placebo-adjusted change of -5.5 points. ABCL635 was described as well tolerated, with no serious or severe adverse events in the active arm, no meaningful liver or gastrointestinal safety signal, and headache, fatigue, and injection-site reactions as the most common events. The company plans 12-week follow-up, additional data presentations, and regulatory interactions to discuss late-stage development.

AbCellera Biologics Inc. announced it will release top-line data from its Phase 2 trial of ABCL635 for the treatment of moderate-to-severe vasomotor symptoms due to menopause on August 10, 2026, and will host an investor conference call that morning.

ABCL635 is described as a potential first-in-class, non-hormonal antibody targeting NK3R, a clinically validated G protein-coupled receptor expressed on KNDy neurons in the hypothalamus. The Phase 2 trial (NCT07118891) is a multicenter, randomized, double-blind, placebo-controlled study in approximately 80 postmenopausal women evaluating reduction in the frequency and severity of vasomotor symptoms. ABCL635 is the first program from AbCellera’s GPCR and ion channel platform to enter the clinic, having done so in July 2025.